One Amgen Center Drive
At Amgen, our mission—to serve patients—drives all that we do. This sense of shared purpose has allowed us to become one of the world’s leading biotechnology companies as we continue to launch new medicines at unprecedented rates and reach millions of patients worldwide.
We collaborate with world-class talent, utilize the industry’s largest toolkit of modalities, and leverage industry-leading partnerships and state-of-the-art technology to develop new processes and products that can turn the tide of serious, life-interrupting illnesses.
As a values-based organization, we aim to make a positive impact on the world. From investments in education to inspire future generations of scientists, to rewarding our colleagues with robust family-centered benefits, we believe in making a difference in the lives of our patients, staff and communities.
At Amgen, we believe in the power of tomorrow and it shows.
Discover what Amgen can do for you by visiting careers.amgen.com.
For more information, visit
www.amgen.com, LinkedIn and follow us on www.twitter.com/amgencareers.
Tweets by Amgen
The Amgen Difference
2069 articles with Amgen
As the number of diagnosed cases of COVID-19 continue to increase across the globe and more and more governments are urging citizens to self-quarantine, the pharmaceutical and life sciences industry continues to work toward the development of a vaccine and therapies for the respiratory infection ...
Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.60 per share dividend for the second quarter of 2020.
3/2/2020The month of February ended with a flurry of clinical trial announcements. Here’s a look.
Amgen (NASDAQ:AMGN) will present at the Cowen 40 th Annual Healthcare Conference at 11:20 a.m. ET on Monday, March 2, 2020 in Boston. Peter H. Griffith , executive vice president and chief financial officer, and Murdo Gordon , executive vice president of Global Commercial Operations at Amgen will present.
The most recent BioSpace Ideal Employer Report revealed the impact of team dynamics on employees within life sciences organizations.
The BioSpace Ideal Employer Report examined aspects regarding the importance of culture within life sciences organizations.
New Amgen Survey Shows Heart Attack Survivors in Canada Do Not Know Their Cholesterol Level or What It Should Be
The biotech Hotbed known as Pharm Country, which includes New Jersey, Connecticut, New York Pennsylvania and Rhode Island, is an area of rapid growth and change.
In honor of Black History Month, BioSpace chose to highlight 10 African American leaders in the life sciences, individuals who have prominent roles in the life sciences and biopharmaceutical industry.
Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2019 versus comparable periods in 2018.
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregiv...
Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2019 financial results on Thursday, Jan. 30, 2020, after the close of the U.S. financial markets.
Free "LabXchange" Science Education Accelerator Launched By Amgen Foundation And Harvard's Faculty Of Arts And Sciences
LabXchange by Amgen Foundation and Harvard's Faculty of Arts and Sciences Reimagines the Science Experience for Students around the Globe
Here’s a look at the top 10 companies noted in the BioSpace Ideal Employer 2019 survey for being the most innovative and what they’ve been up to recently.
With the 2020 elections looming though, and lawmakers across the country drafting legislation aimed at curbing price increases, some companies are carefully examining the landscape as they approach pricing.
What's New at the J.P. Morgan Life Healthcare Conference?
Amgen Announces Global Diagnostic Collaborations To Expand Molecular Testing For Patients With Non-Small Cell Lung Cancer
First Company Developing a KRAS(G12C) Inhibitor to Announce Multi-Platform Companion Diagnostics
QIAGEN Builds on Global Collaboration With Amgen for Companion Diagnostic Development in Non-small Cell Lung Cancer
QIAGEN and Amgen to develop tissue-based therascreen® test, paired with investigational treatment AMG 510, to identify patients whose cancers have KRAS G12C mutation
Guardant Health Announces Collaboration With Amgen to Develop a Global Liquid Biopsy Companion Diagnostic for AMG 510 KRAS G12C Inhibitor
Guardant Health, Inc., announces a strategic collaboration to develop and help support commercialization of a blood-based companion diagnostic test for Amgen’s AMG 510, an investigational oral therapy that inhibits KRAS G12C mutant protein, globally.
Amgen (NASDAQ:AMGN) will present at the 38th Annual J.P. Morgan Healthcare Conference at 8:30 a.m. PT on Tuesday, Jan. 14, 2020, in San Francisco.